Brind.

The FDA approved additional iohexol injection strengths, with Amneal aiming to meet U.S. market demand.

1 report, 1 independent Updated Jul 17

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

FDA Amneal Pharmaceuticals, Inc.

Keep exploring

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
Amneal Pharmaceuticals, Inc.
American publicly traded generics and specialty pharmaceutical company

Nothing else this week.

Related events

Coverage

Newest first; wire copies grouped

Jul 17finanznachrichten.de